AstraZeneca PLC
AZN
$77.46
-$0.50-0.64%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 1.50B | 1.43B | 1.93B | 2.18B | 960.00M |
Total Depreciation and Amortization | 1.16B | 1.32B | 1.25B | 1.26B | 1.17B |
Total Amortization of Deferred Charges | 200.00M | -- | -- | -- | 280.00M |
Total Other Non-Cash Items | 402.00M | 595.00M | 34.00M | -493.00M | -177.00M |
Change in Net Operating Assets | -350.00M | 41.00M | -129.00M | -455.00M | 150.00M |
Cash from Operations | 2.91B | 3.38B | 3.09B | 2.49B | 2.38B |
Capital Expenditure | -708.00M | -417.00M | -382.00M | -417.00M | -525.00M |
Sale of Property, Plant, and Equipment | 2.00M | 0.00 | 0.00 | 53.00M | 1.00M |
Cash Acquisitions | -274.00M | -263.00M | -2.30B | -948.00M | -216.00M |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -201.00M | -834.00M | -193.00M | -1.10B | -337.00M |
Cash from Investing | -1.18B | -1.51B | -2.87B | -2.41B | -1.08B |
Total Debt Issued | -572.00M | -415.00M | 1.50B | 5.98B | 51.00M |
Total Debt Repaid | -119.00M | -2.09B | -2.71B | -81.00M | -361.00M |
Issuance of Common Stock | 23.00M | 4.00M | 5.00M | 6.00M | 21.00M |
Repurchase of Common Stock | 0.00 | -81.00M | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -1.58B | -17.00M | -3.03B | -12.00M |
Other Financing Activities | -23.00M | 24.00M | 0.00 | -841.00M | 10.00M |
Cash from Financing | -671.00M | -4.13B | -1.22B | 2.03B | -291.00M |
Foreign Exchange rate Adjustments | -61.00M | 20.00M | -6.00M | -46.00M | 6.00M |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 994.00M | -2.24B | -1.02B | 2.06B | 1.02B |